FeetMe develops smart medical wearables—connected insoles—combined with pressure sensors, motion sensors and learning algorithms to perform real-world gait and posture analysis. The company positions its platform as the world’s first and most advanced solution for real-world disease diagnostics, monitoring and rehabilitation based on movement data. FeetMe says its technology can generate unique insights and real-world evidence to accelerate clinical research at scale and to empower rehabilitation for patients with gait disorders. The fundraising will be used to develop new digital health services and accelerate commercial activities in clinical trials for the pharmaceutical industry and for hospitals and rehabilitation facilities worldwide. The company notes that about 100 million people globally suffer from gait disorders, which are indicators for conditions such as multiple sclerosis, Parkinson’s disease, peripheral neuropathies and diabetic foot problems. FeetMe is a certified medical device company focused on long-term continuous mobility assessment and building large gait-pattern datasets to enable new digital biomarkers. FeetMe is a Paris, France-based medical device company led by founder and CEO Alexis Mathieu. The company produces smart and connected insoles that combine pressure sensors, motion sensors and learning algorithms to analyze patients’ functional capacity and support running, walking and gait analysis. Its technology is positioned to empower rehabilitation among sufferers of gait disorders. FeetMe raised €1.95m in seed funding to advance product development. The company intends to use the funds to pursue development of its product to target therapeutic areas in collaboration with market players. The financing includes participation from strategic and specialty healthcare investors.

Total raised

$13M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2019